 Jeffrey Kaplan
Concepts (378)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biofilms | 39 | 2025 | 292 | 8.760 |
Why?
| | Aggregatibacter actinomycetemcomitans | 22 | 2024 | 27 | 3.840 |
Why?
| | Staphylococcus epidermidis | 15 | 2025 | 79 | 3.150 |
Why?
| | Glycoside Hydrolases | 14 | 2025 | 38 | 3.000 |
Why?
| | Bacterial Proteins | 24 | 2025 | 976 | 2.720 |
Why?
| | Anti-Bacterial Agents | 17 | 2025 | 1940 | 2.120 |
Why?
| | Polysaccharides, Bacterial | 13 | 2015 | 69 | 2.070 |
Why?
| | Bacterial Adhesion | 18 | 2018 | 109 | 1.970 |
Why?
| | Staphylococcus aureus | 9 | 2018 | 458 | 1.720 |
Why?
| | DNA, Bacterial | 11 | 2024 | 320 | 1.380 |
Why?
| | Actinobacillus pleuropneumoniae | 5 | 2013 | 5 | 1.370 |
Why?
| | Kingella kingae | 3 | 2016 | 12 | 1.190 |
Why?
| | Microbial Sensitivity Tests | 10 | 2025 | 367 | 0.980 |
Why?
| | Acetylglucosamine | 6 | 2008 | 14 | 0.910 |
Why?
| | Benzoyl Peroxide | 1 | 2025 | 2 | 0.890 |
Why?
| | Propionibacteriaceae | 1 | 2025 | 2 | 0.890 |
Why?
| | Propionibacterium acnes | 1 | 2025 | 10 | 0.880 |
Why?
| | Micrococcal Nuclease | 1 | 2024 | 26 | 0.820 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2024 | 251 | 0.820 |
Why?
| | Actinobacillus Infections | 7 | 2008 | 7 | 0.800 |
Why?
| | Prosthesis-Related Infections | 6 | 2011 | 99 | 0.800 |
Why?
| | Deoxyribonuclease I | 5 | 2018 | 42 | 0.750 |
Why?
| | Bacteria | 5 | 2014 | 769 | 0.740 |
Why?
| | Adhesins, Bacterial | 6 | 2010 | 44 | 0.740 |
Why?
| | Extracellular Space | 2 | 2012 | 117 | 0.670 |
Why?
| | Amoxicillin | 2 | 2024 | 35 | 0.660 |
Why?
| | Povidone-Iodine | 2 | 2018 | 12 | 0.640 |
Why?
| | Staphylococcal Skin Infections | 1 | 2018 | 40 | 0.540 |
Why?
| | Molecular Sequence Data | 17 | 2012 | 2886 | 0.520 |
Why?
| | Cetylpyridinium | 4 | 2009 | 5 | 0.490 |
Why?
| | Neisseriaceae Infections | 2 | 2016 | 6 | 0.490 |
Why?
| | beta-Lactams | 2 | 2016 | 32 | 0.480 |
Why?
| | Virulence Factors | 3 | 2024 | 175 | 0.440 |
Why?
| | Exotoxins | 4 | 2008 | 16 | 0.430 |
Why?
| | Pasteurellaceae | 3 | 2010 | 3 | 0.420 |
Why?
| | Genome, Bacterial | 2 | 2012 | 123 | 0.410 |
Why?
| | Genes, Bacterial | 5 | 2004 | 152 | 0.400 |
Why?
| | Bacterial Capsules | 1 | 2013 | 33 | 0.390 |
Why?
| | Arthritis, Infectious | 1 | 2012 | 77 | 0.330 |
Why?
| | Sodium Dodecyl Sulfate | 2 | 2009 | 25 | 0.330 |
Why?
| | Drug Resistance, Bacterial | 4 | 2018 | 185 | 0.330 |
Why?
| | Pasteurellaceae Infections | 2 | 2024 | 2 | 0.320 |
Why?
| | Recombination, Genetic | 1 | 2011 | 205 | 0.320 |
Why?
| | Fimbriae, Bacterial | 3 | 2016 | 36 | 0.320 |
Why?
| | Extracellular Matrix | 2 | 2014 | 566 | 0.310 |
Why?
| | Periodontitis | 5 | 2006 | 55 | 0.310 |
Why?
| | Pancreatic Neoplasms | 4 | 2024 | 947 | 0.310 |
Why?
| | Staphylococcus | 2 | 2007 | 74 | 0.310 |
Why?
| | Enzyme Therapy | 1 | 2009 | 4 | 0.300 |
Why?
| | beta-Glucans | 1 | 2008 | 16 | 0.290 |
Why?
| | Mouth | 2 | 2015 | 86 | 0.290 |
Why?
| | Down-Regulation | 1 | 2011 | 618 | 0.280 |
Why?
| | Aggressive Periodontitis | 3 | 2003 | 3 | 0.280 |
Why?
| | Polysaccharides | 2 | 2008 | 89 | 0.280 |
Why?
| | Mouth Mucosa | 2 | 2007 | 85 | 0.280 |
Why?
| | Haemophilus influenzae | 1 | 2009 | 68 | 0.280 |
Why?
| | Disinfectants | 1 | 2009 | 45 | 0.280 |
Why?
| | Fusobacterium nucleatum | 1 | 2008 | 4 | 0.270 |
Why?
| | Dental Plaque | 1 | 2008 | 19 | 0.270 |
Why?
| | Bacterial Infections | 1 | 2010 | 247 | 0.260 |
Why?
| | Cefamandole | 1 | 2007 | 1 | 0.260 |
Why?
| | Adenocarcinoma | 3 | 2024 | 928 | 0.260 |
Why?
| | Bacterial Physiological Phenomena | 3 | 2014 | 47 | 0.260 |
Why?
| | Galactans | 1 | 2007 | 3 | 0.250 |
Why?
| | Polyurethanes | 1 | 2007 | 38 | 0.250 |
Why?
| | Sequence Analysis, DNA | 6 | 2009 | 780 | 0.250 |
Why?
| | Surface-Active Agents | 1 | 2007 | 98 | 0.240 |
Why?
| | Humans | 45 | 2025 | 147293 | 0.240 |
Why?
| | Drug Resistance | 1 | 2007 | 145 | 0.240 |
Why?
| | Recombinant Proteins | 5 | 2018 | 1371 | 0.220 |
Why?
| | Swine Diseases | 1 | 2005 | 9 | 0.220 |
Why?
| | O Antigens | 2 | 2003 | 8 | 0.220 |
Why?
| | Acne Vulgaris | 1 | 2025 | 25 | 0.220 |
Why?
| | Fimbriae Proteins | 3 | 2016 | 25 | 0.210 |
Why?
| | Drug Synergism | 1 | 2025 | 355 | 0.200 |
Why?
| | Serotyping | 4 | 2008 | 31 | 0.200 |
Why?
| | Species Specificity | 4 | 2011 | 547 | 0.200 |
Why?
| | Acetylglucosaminidase | 1 | 2003 | 8 | 0.200 |
Why?
| | Animals | 17 | 2024 | 38410 | 0.190 |
Why?
| | Genetic Variation | 3 | 2002 | 995 | 0.190 |
Why?
| | Neisseria | 1 | 2002 | 2 | 0.190 |
Why?
| | Bacteria, Anaerobic | 1 | 2002 | 25 | 0.180 |
Why?
| | Base Sequence | 6 | 2012 | 2175 | 0.180 |
Why?
| | Gene Transfer, Horizontal | 2 | 2016 | 34 | 0.170 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2021 | 62 | 0.170 |
Why?
| | Amino Acid Sequence | 7 | 2008 | 2134 | 0.160 |
Why?
| | Polymerase Chain Reaction | 5 | 2008 | 1046 | 0.160 |
Why?
| | Gram-Negative Bacteria | 1 | 2001 | 80 | 0.160 |
Why?
| | Gastroesophageal Reflux | 1 | 2023 | 237 | 0.160 |
Why?
| | Osteopontin | 1 | 2020 | 37 | 0.160 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 39 | 0.160 |
Why?
| | Barrett Esophagus | 1 | 2023 | 172 | 0.160 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2021 | 196 | 0.160 |
Why?
| | Macrophages | 1 | 2008 | 1529 | 0.150 |
Why?
| | Microfluidics | 2 | 2010 | 61 | 0.150 |
Why?
| | Codon | 2 | 1998 | 92 | 0.150 |
Why?
| | DNA Transposable Elements | 4 | 2008 | 125 | 0.150 |
Why?
| | Polystyrenes | 3 | 2004 | 38 | 0.150 |
Why?
| | Microfluidic Analytical Techniques | 2 | 2010 | 79 | 0.140 |
Why?
| | Esophageal Neoplasms | 1 | 2023 | 351 | 0.140 |
Why?
| | Sus scrofa | 1 | 2018 | 66 | 0.140 |
Why?
| | Colony Count, Microbial | 2 | 2009 | 90 | 0.140 |
Why?
| | Escherichia coli | 5 | 2010 | 836 | 0.130 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.130 |
Why?
| | Weight Gain | 1 | 2021 | 566 | 0.130 |
Why?
| | Pancreatic Cyst | 1 | 2018 | 50 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 266 | 0.130 |
Why?
| | Liver | 2 | 2020 | 1916 | 0.130 |
Why?
| | Adipose Tissue | 1 | 2021 | 646 | 0.130 |
Why?
| | Epithelial Cells | 3 | 2010 | 1141 | 0.130 |
Why?
| | Endopeptidase K | 1 | 2016 | 18 | 0.130 |
Why?
| | Biopsy | 2 | 2018 | 1093 | 0.120 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 123 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 379 | 0.120 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2015 | 8 | 0.120 |
Why?
| | Mutagenesis, Insertional | 3 | 2008 | 69 | 0.110 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 395 | 0.110 |
Why?
| | Nausea | 1 | 2015 | 112 | 0.110 |
Why?
| | Myositis | 1 | 2015 | 57 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 153 | 0.110 |
Why?
| | Air | 1 | 2014 | 44 | 0.110 |
Why?
| | Acinetobacter baumannii | 1 | 2014 | 26 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2016 | 146 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2001 | 1171 | 0.110 |
Why?
| | Bone Resorption | 1 | 2015 | 81 | 0.100 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2007 | 627 | 0.100 |
Why?
| | Environmental Microbiology | 1 | 2014 | 47 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 87 | 0.100 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.100 |
Why?
| | Abdominal Pain | 1 | 2015 | 149 | 0.100 |
Why?
| | Immunoglobulins | 1 | 2014 | 163 | 0.100 |
Why?
| | Anilides | 1 | 2014 | 84 | 0.100 |
Why?
| | Plankton | 1 | 2014 | 8 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 76 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2030 | 0.100 |
Why?
| | Surface Properties | 4 | 2012 | 386 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 222 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2019 | 787 | 0.090 |
Why?
| | Molecular Weight | 1 | 2013 | 313 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2014 | 3565 | 0.090 |
Why?
| | Pancreas | 1 | 2014 | 345 | 0.090 |
Why?
| | Coated Materials, Biocompatible | 1 | 2012 | 65 | 0.090 |
Why?
| | Cell Survival | 3 | 2012 | 1111 | 0.090 |
Why?
| | Female | 15 | 2024 | 80076 | 0.090 |
Why?
| | Tobramycin | 1 | 2011 | 63 | 0.090 |
Why?
| | Microscopy, Electron | 2 | 2003 | 417 | 0.090 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4604 | 0.080 |
Why?
| | Cell Communication | 1 | 2013 | 329 | 0.080 |
Why?
| | Genetic Complementation Test | 2 | 2008 | 72 | 0.080 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2014 | 299 | 0.080 |
Why?
| | Culture Media | 3 | 2010 | 161 | 0.080 |
Why?
| | Orthopedic Equipment | 1 | 2010 | 5 | 0.080 |
Why?
| | Biomarkers, Tumor | 2 | 2014 | 1339 | 0.080 |
Why?
| | Treatment Failure | 1 | 2011 | 360 | 0.080 |
Why?
| | Fungi | 1 | 2011 | 122 | 0.080 |
Why?
| | Pyridines | 1 | 2014 | 610 | 0.080 |
Why?
| | Focal Nodular Hyperplasia | 1 | 2010 | 7 | 0.080 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2002 | 512 | 0.080 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2007 | 62 | 0.080 |
Why?
| | Bacterial Toxins | 2 | 2002 | 109 | 0.080 |
Why?
| | Escherichia coli Proteins | 1 | 2011 | 201 | 0.080 |
Why?
| | Titanium | 1 | 2010 | 74 | 0.080 |
Why?
| | DNA Primers | 2 | 2007 | 505 | 0.070 |
Why?
| | Disease Transmission, Infectious | 1 | 2010 | 69 | 0.070 |
Why?
| | Osteoblasts | 1 | 2010 | 146 | 0.070 |
Why?
| | Drug Interactions | 2 | 2008 | 405 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 2010 | 137 | 0.070 |
Why?
| | Enzymes | 1 | 2009 | 60 | 0.070 |
Why?
| | Sodium Hypochlorite | 1 | 2009 | 6 | 0.070 |
Why?
| | Convection | 1 | 2008 | 7 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2008 | 387 | 0.070 |
Why?
| | Mutation | 5 | 2009 | 4130 | 0.070 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 337 | 0.070 |
Why?
| | Chlorhexidine | 1 | 2009 | 24 | 0.070 |
Why?
| | Flagella | 1 | 1989 | 27 | 0.070 |
Why?
| | Azo Compounds | 1 | 2008 | 30 | 0.070 |
Why?
| | Diffusion | 1 | 2008 | 120 | 0.070 |
Why?
| | Phosphoenolpyruvate Sugar Phosphotransferase System | 1 | 2008 | 4 | 0.070 |
Why?
| | Phylogeny | 2 | 2002 | 924 | 0.070 |
Why?
| | Catalytic Domain | 2 | 2008 | 234 | 0.070 |
Why?
| | Caenorhabditis elegans | 1 | 2011 | 330 | 0.070 |
Why?
| | beta-N-Acetylhexosaminidases | 1 | 2007 | 9 | 0.070 |
Why?
| | Obesity | 1 | 2021 | 3149 | 0.070 |
Why?
| | Congo Red | 1 | 2007 | 8 | 0.070 |
Why?
| | Gene Order | 1 | 2007 | 29 | 0.070 |
Why?
| | Tritium | 1 | 2007 | 67 | 0.070 |
Why?
| | Pancreatectomy | 2 | 2024 | 290 | 0.070 |
Why?
| | Male | 12 | 2024 | 73950 | 0.060 |
Why?
| | Detergents | 1 | 2007 | 43 | 0.060 |
Why?
| | Quorum Sensing | 1 | 2008 | 80 | 0.060 |
Why?
| | Micelles | 1 | 2007 | 39 | 0.060 |
Why?
| | Chromosomes, Bacterial | 1 | 2007 | 12 | 0.060 |
Why?
| | Glycosyltransferases | 1 | 2007 | 16 | 0.060 |
Why?
| | Ampicillin | 1 | 2007 | 17 | 0.060 |
Why?
| | Periodic Acid | 1 | 2007 | 2 | 0.060 |
Why?
| | Pancreatin | 1 | 2007 | 6 | 0.060 |
Why?
| | Ligands | 2 | 2008 | 675 | 0.060 |
Why?
| | Glycogen Storage Disease Type IV | 1 | 2006 | 4 | 0.060 |
Why?
| | 1,4-alpha-Glucan Branching Enzyme | 1 | 2006 | 4 | 0.060 |
Why?
| | Carbohydrate Sequence | 2 | 2008 | 29 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2014 | 876 | 0.060 |
Why?
| | Middle Aged | 8 | 2024 | 36821 | 0.060 |
Why?
| | Peptide Hydrolases | 1 | 2007 | 105 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2625 | 0.060 |
Why?
| | Cohort Studies | 3 | 2024 | 6099 | 0.060 |
Why?
| | Pleuropneumonia | 1 | 2005 | 1 | 0.060 |
Why?
| | Carbohydrate Conformation | 1 | 2005 | 16 | 0.060 |
Why?
| | Gene Deletion | 1 | 2007 | 392 | 0.060 |
Why?
| | Hydrogels | 2 | 2012 | 706 | 0.060 |
Why?
| | Static Electricity | 1 | 2005 | 115 | 0.050 |
Why?
| | Virulence | 2 | 2003 | 286 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2006 | 196 | 0.050 |
Why?
| | Mice | 5 | 2021 | 18491 | 0.050 |
Why?
| | Carbohydrate Metabolism | 1 | 2004 | 59 | 0.050 |
Why?
| | Primates | 1 | 2005 | 133 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 372 | 0.050 |
Why?
| | Aged | 6 | 2024 | 26514 | 0.050 |
Why?
| | Lactoferrin | 1 | 2003 | 37 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 184 | 0.050 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 649 | 0.050 |
Why?
| | Child, Preschool | 2 | 2016 | 12016 | 0.050 |
Why?
| | Metaplasia | 1 | 2023 | 57 | 0.050 |
Why?
| | Transcription, Genetic | 3 | 2020 | 1456 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2231 | 0.050 |
Why?
| | Adult | 7 | 2020 | 41405 | 0.050 |
Why?
| | Sequence Analysis, Protein | 1 | 2002 | 32 | 0.050 |
Why?
| | Agar | 1 | 2002 | 11 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 855 | 0.050 |
Why?
| | Bacteriological Techniques | 1 | 2003 | 66 | 0.050 |
Why?
| | Child | 3 | 2016 | 22979 | 0.050 |
Why?
| | Swine | 1 | 2005 | 828 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2010 | 841 | 0.050 |
Why?
| | Promoter Regions, Genetic | 2 | 2009 | 1253 | 0.040 |
Why?
| | Conserved Sequence | 1 | 2002 | 244 | 0.040 |
Why?
| | DNA, Ribosomal | 1 | 2002 | 84 | 0.040 |
Why?
| | Mice, Obese | 1 | 2021 | 68 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2003 | 372 | 0.040 |
Why?
| | Esophagoscopy | 1 | 2023 | 223 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2016 | 1492 | 0.040 |
Why?
| | Thinness | 1 | 2021 | 100 | 0.040 |
Why?
| | Aromatase Inhibitors | 1 | 2021 | 81 | 0.040 |
Why?
| | Genotype | 2 | 2003 | 1875 | 0.040 |
Why?
| | Phenotype | 2 | 2010 | 3216 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 474 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1569 | 0.040 |
Why?
| | Tamoxifen | 1 | 2021 | 193 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2001 | 148 | 0.040 |
Why?
| | Protein Precursors | 1 | 2001 | 136 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1772 | 0.040 |
Why?
| | Mutagenesis | 1 | 2001 | 196 | 0.040 |
Why?
| | Coculture Techniques | 2 | 2010 | 247 | 0.040 |
Why?
| | Alleles | 1 | 2002 | 909 | 0.040 |
Why?
| | Temperature | 1 | 2002 | 638 | 0.040 |
Why?
| | Adolescent | 4 | 2010 | 22825 | 0.040 |
Why?
| | Protein Binding | 1 | 2005 | 2249 | 0.040 |
Why?
| | Base Composition | 1 | 1998 | 82 | 0.030 |
Why?
| | Genetic Code | 1 | 1998 | 24 | 0.030 |
Why?
| | ROC Curve | 1 | 2020 | 626 | 0.030 |
Why?
| | Cyst Fluid | 1 | 2018 | 20 | 0.030 |
Why?
| | Carcinoembryonic Antigen | 1 | 2018 | 40 | 0.030 |
Why?
| | Cell Movement | 1 | 2002 | 966 | 0.030 |
Why?
| | Hydrolysis | 2 | 2008 | 197 | 0.030 |
Why?
| | Infant | 1 | 2012 | 10194 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2018 | 51 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2018 | 62 | 0.030 |
Why?
| | Substrate Specificity | 2 | 2008 | 387 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2010 | 3022 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 980 | 0.030 |
Why?
| | Endosonography | 1 | 2018 | 162 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2016 | 37 | 0.030 |
Why?
| | Giant Cells | 1 | 2016 | 21 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1166 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 8430 | 0.030 |
Why?
| | Cell Line | 2 | 2012 | 2832 | 0.030 |
Why?
| | Binding Sites | 2 | 2010 | 1319 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2024 | 11947 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 222 | 0.030 |
Why?
| | CD3 Complex | 1 | 2015 | 113 | 0.030 |
Why?
| | Monosaccharides | 1 | 2014 | 14 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 2017 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 429 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2014 | 76 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2014 | 200 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2015 | 2542 | 0.030 |
Why?
| | Intestine, Small | 1 | 2015 | 168 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 2001 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 108 | 0.030 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2014 | 194 | 0.030 |
Why?
| | Time Factors | 3 | 2010 | 7173 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 1059 | 0.020 |
Why?
| | Lymphocytes | 1 | 2015 | 378 | 0.020 |
Why?
| | Microscopy | 1 | 2014 | 148 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2018 | 1147 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 891 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 862 | 0.020 |
Why?
| | Models, Molecular | 2 | 2008 | 1606 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 287 | 0.020 |
Why?
| | Colon | 1 | 2015 | 310 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 680 | 0.020 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 239 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3660 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2890 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2014 | 383 | 0.020 |
Why?
| | Polymethacrylic Acids | 1 | 2012 | 61 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 440 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2009 | 1794 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1598 | 0.020 |
Why?
| | Rats | 2 | 2015 | 5613 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 939 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1518 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 2110 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1172 | 0.020 |
Why?
| | Propidium | 1 | 2010 | 8 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 6041 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2010 | 157 | 0.020 |
Why?
| | Cell Shape | 1 | 2010 | 56 | 0.020 |
Why?
| | Alloys | 1 | 2010 | 37 | 0.020 |
Why?
| | Siphoviridae | 1 | 2009 | 2 | 0.020 |
Why?
| | Artificial Gene Fusion | 1 | 2009 | 3 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2009 | 5 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 373 | 0.020 |
Why?
| | Protein Hydrolysates | 1 | 2008 | 6 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2010 | 451 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2012 | 863 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 409 | 0.020 |
Why?
| | Caseins | 1 | 2008 | 20 | 0.020 |
Why?
| | Nucleotides | 1 | 2009 | 129 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2009 | 278 | 0.020 |
Why?
| | Buffers | 1 | 2008 | 56 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1457 | 0.020 |
Why?
| | Oligosaccharides | 1 | 2008 | 61 | 0.020 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2008 | 196 | 0.020 |
Why?
| | Multigene Family | 1 | 1989 | 210 | 0.020 |
Why?
| | Rifampin | 1 | 2008 | 79 | 0.020 |
Why?
| | Microscopy, Atomic Force | 1 | 2008 | 129 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 407 | 0.020 |
Why?
| | Cercopithecidae | 1 | 2007 | 7 | 0.020 |
Why?
| | Sodium Chloride | 1 | 2008 | 138 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2008 | 362 | 0.020 |
Why?
| | Orthopedics | 1 | 2010 | 181 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2008 | 208 | 0.020 |
Why?
| | Phosphates | 1 | 2008 | 177 | 0.020 |
Why?
| | Teichoic Acids | 1 | 2007 | 20 | 0.020 |
Why?
| | Abortion, Eugenic | 1 | 2006 | 2 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2007 | 377 | 0.020 |
Why?
| | Hip Prosthesis | 1 | 2006 | 42 | 0.020 |
Why?
| | Thermodynamics | 1 | 2008 | 420 | 0.020 |
Why?
| | Equipment Design | 1 | 2008 | 527 | 0.020 |
Why?
| | Knee Prosthesis | 1 | 2006 | 30 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 587 | 0.010 |
Why?
| | Hemolysis | 1 | 2008 | 242 | 0.010 |
Why?
| | Genome Components | 1 | 2006 | 2 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 536 | 0.010 |
Why?
| | Tissue Engineering | 1 | 2010 | 439 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2006 | 306 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4383 | 0.010 |
Why?
| | Protein Transport | 1 | 2007 | 442 | 0.010 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 154 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2012 | 2054 | 0.010 |
Why?
| | Calcium | 1 | 2010 | 1197 | 0.010 |
Why?
| | Spodoptera | 1 | 2003 | 40 | 0.010 |
Why?
| | Computer Simulation | 1 | 2008 | 1018 | 0.010 |
Why?
| | Alveolar Bone Loss | 1 | 2003 | 9 | 0.010 |
Why?
| | Maxilla | 1 | 2003 | 36 | 0.010 |
Why?
| | Genetic Testing | 1 | 2006 | 493 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2003 | 539 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2529 | 0.010 |
Why?
| | Adenosine Triphosphatases | 1 | 2003 | 159 | 0.010 |
Why?
| | Iron | 1 | 2003 | 361 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2003 | 615 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 5272 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1989 | 2812 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1444 | 0.010 |
Why?
| | United States | 1 | 2016 | 16313 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 17560 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6543 | 0.010 |
Why?
| | Pregnancy | 1 | 2006 | 7274 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2006 | 2218 | 0.010 |
Why?
|
|
Kaplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|